Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals, Protein Kinase and Activators,
No Data Available
SB 202190 is a DFG inhibitor used in the treatment of colorectal cancer. It is a highly selective, potent inhibitor of p38 MAP kinase. SB-202190 is able to promote proliferation of C6 cells in lower concentration but induced apoptosis in higher levels. Studies show that SB202190 can protect neural function from ischemia/reperfusion injury and regulate the activation of Bcl-2 and Bax protein after ischemia/reperfusion in rat.